We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
- Authors
Yalu Liu; Xiaogan Wang; Ning Ding; Lan Mi; Lingyan Ping; Xuan Jin; Jiao Li; Yan Xie; Zhitao Ying; Weiping Liu; Chen Zhang; Lijuan Deng; Yuqin Song; Jun Zhu; Liu, Yalu; Wang, Xiaogan; Ding, Ning; Mi, Lan; Ping, Lingyan; Jin, Xuan
- Abstract
<bold>Background: </bold>TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asians is unknown.<bold>Methods: </bold>Genotyping of TP53 Arg72Pro was done in 425 Chinese DLBCL patients. Two hundred and eighty-nine patients were treated with R-CHOP, and 136 patients received CHOP or CHOP-like as frontline regimen. Three hundred and ninety-six patients were assessable for the efficacy.<bold>Results: </bold>Patients with Arg/Arg and Arg/Pro at codon 72 of TP53 had a higher complete response rate (61% vs. 44%, P = 0.007) than those with Pro/Pro. In the subgroup treated with CHOP or CHOP-like therapy, patients with Arg/Arg and Arg/Pro showed a higher 5-year overall survival (OS) rate than those with Pro/Pro (68.8% vs. 23.2%, P = 0.001). Multivariate Cox regression analysis revealed TP53 Arg72 as a favorable prognostic factor in this group. However, the combination of rituximab with CHOP significantly increased the 5-year OS rate of patients with Pro/Pro to 63%.<bold>Conclusion: </bold>This study revealed TP53 Arg72 as a favorable prognostic factor for Chinese DLBCL patients treated with CHOP or CHOP-like as frontline therapy.
- Subjects
P53 protein; SINGLE nucleotide polymorphisms; DIFFUSE large B-cell lymphomas; CANCER prognosis; RITUXIMAB; CANCER chemotherapy; DIAGNOSIS; ANTINEOPLASTIC agents; B cell lymphoma; DOXORUBICIN; GENETIC polymorphisms; PREDNISONE; PROGNOSIS; PROTEINS; VINCRISTINE; TREATMENT effectiveness; DISEASE remission; CYCLOPHOSPHAMIDE; GENOTYPES
- Publication
BMC Cancer, 2017, Vol 17, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-017-3760-0